Labopharm falls on trazodone delay in Canada

Shares of Labopharm Inc. (TSX:DDS; NASDAQ:DDSS) fell on Thursday after Health Canada delayed a decision on an NDS for once-daily trazodone to treat major depressive disorder (MDD) due to an internal backlog at the agency. Labopharm, which originally expected a decision by Aug. 12, now expects a decision by year end. The company said the agency has not informed them of any issues with the application. Labopharm was down C$0.17 (14%) to C$1.05 on Thursday. On NASDAQ, the stock was down $0.09 to $1.03. ...